Modulation of Epidermal Growth Factor Receptor in Endocrine-Resistant, Estrogen-Receptor-Positive Breast Cancer

: An increasing body of evidence demonstrates that growth factor networks are highly interactive with estrogen receptor signaling in the control of breast cancer growth. As such, tumor responses to antihormones are likely to be a composite of the estrogen receptor and growth factor inhibitory activi...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the New York Academy of Sciences 2002-06, Vol.963 (1), p.104-115
Main Authors: NICHOLSON, R. I., HUTCHESON, I. R., HARPER, M. E., KNOWLDEN, J. M., BARROW, D., McCLELLAND, R. A., JONES, H. E., WAKELING, A. E., GEE, J.M. W.
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - pharmacology
breast cancer
Breast Neoplasms - metabolism
Cell Division - drug effects
Drug Resistance, Neoplasm - physiology
Endocrine Glands
ErbB Receptors - metabolism
Estradiol - analogs & derivatives
Estradiol - pharmacology
estrogen receptor
Estrogen Receptor Modulators - pharmacology
Female
Fulvestrant
Gefitinib
Humans
Protein-Tyrosine Kinases - antagonists & inhibitors
Quinazolines - pharmacology
Receptor, ErbB-2 - physiology
Receptors, Estrogen - metabolism
Signal Transduction - drug effects
Signal Transduction - physiology
Tamoxifen - pharmacology
Trastuzumab
Tumor Cells, Cultured
tyrosine kinase inhibitor
ZD 1839
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:: An increasing body of evidence demonstrates that growth factor networks are highly interactive with estrogen receptor signaling in the control of breast cancer growth. As such, tumor responses to antihormones are likely to be a composite of the estrogen receptor and growth factor inhibitory activity of these agents. The modulation of growth factor networks during endocrine response is examined, and in vitro and clinical evidence is presented that epidermal growth factor receptor signaling, maintained in either an estrogen receptor‐dependent or a receptor‐independent manner, is critical to antihormone‐resistant breast cancer cell growth. The considerable potential of the epidermal growth factor receptor‐selective tyrosine kinase inhibitor Iressa (ZD 1839) to efficiently treat, and perhaps even prevent, endocrine‐resistant breast cancer is highlighted.
ISSN:0077-8923
1749-6632
DOI:10.1111/j.1749-6632.2002.tb04101.x